CTOs on the Move

Encodia

www.encodia.com

 
Encodia is developing an innovative Next-Gen digital proteomics platform to enable democratized protein sequencing. Our goal is to make protein sequencing easy and ubiquitous by using a novel reverse-translation technology that turns peptide sequences into DNA. The DNA can be read by an NGS DNA sequencer, providing a path to breakthrough proteomics research at a scale that is not practical or cost-effective using current technologies.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.encodia.com
  • 11045 Roselle Street Suite #120
    San Diego, CA USA 92121
  • Phone: 858.345.6272

Executives

Name Title Contact Details
Kevin Gunderson
Chief Technology Officer Profile
Nigel Beard
Chief Technology Officer Profile

Funding

Encodia raised $60M on 12/22/2020

Similar Companies

Molecular Templates

Molecular Templates is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of a next-generation of immunotoxins for the treatment of cancers. Our Engineered Toxin Bodies (ETBs) platform represent a new class of targeted biologic therapies that possess unique biological properties.

Donor Network of Arizona

Donor Network of Arizona is a Phoenix, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Phio Pharmaceuticals

Developing the next generation of immuno-oncology therapeutics

Allied BioScience

Allied BioScience is a disruptive biotechnology company specializing in continuously active antimicrobial coatings providing 90 days of surface protection. Working across various industries and commercial settings, its customers include health systems, sports facilities, and other commercial partners. The company is dedicated to saving life through revolutionary science and focuses on developing innovative solutions to create cleaner human environments through long-lasting, always-on antimicrobial coatings.

Targacept

Targacept`s clinical pipeline is built on a unique class of therapeutic targets.